These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 361132

  • 1. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
    O'Connor TP, Labandter HP, Hiles RW, Bodenham DC.
    Br J Plast Surg; 1978 Oct; 31(4):317-22. PubMed ID: 361132
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
    Byrne MJ, Van Hazel G, Reynolds PM, Lemish WM, Holman CD.
    J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK, Ibrahim EM, Evers JA, Thomas JW, Murray RN, Spinelli JJ.
    Can Med Assoc J; 1983 Jun 01; 128(11):1291-5. PubMed ID: 6342739
    [Abstract] [Full Text] [Related]

  • 4. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH, Deutschmann EM, Schultheis W, Deicher H.
    Dev Biol Stand; 1983 Jun 01; 38():537-40. PubMed ID: 344106
    [Abstract] [Full Text] [Related]

  • 5. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V, Knopf B.
    Arch Geschwulstforsch; 1981 Jun 01; 51(6):493-6. PubMed ID: 7332442
    [Abstract] [Full Text] [Related]

  • 6. Mumps virus and BCG vaccine in metastatic melanoma.
    Minton JP.
    Arch Surg; 1973 Apr 01; 106(4):503-6. PubMed ID: 4572347
    [No Abstract] [Full Text] [Related]

  • 7. Surgical adjuvant therapy for malignant melanoma.
    Pinsky CM, Oettgen HF.
    Surg Clin North Am; 1981 Dec 01; 61(6):1259-66. PubMed ID: 7031933
    [No Abstract] [Full Text] [Related]

  • 8. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.
    Fisher RI, Terry WD, Hodes RJ, Rosenberg SA, Makuch R, Gordon HG, Fisher SG.
    Surg Clin North Am; 1981 Dec 01; 61(6):1267-77. PubMed ID: 7031934
    [No Abstract] [Full Text] [Related]

  • 9. BCG immunotherapy as a systemic adjunct to surgery in malignant melanoma.
    Morton DL, Eilber FR, Holmes EC, Sparks FC, Ramming K.
    Med Clin North Am; 1976 May 01; 60(3):431-9. PubMed ID: 1271888
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Adjuvant BCG immunotherapy for malignant melanoma.
    Paterson AH, Willans DJ, Jerry LM, Hanson J, McPherson TA.
    Can Med Assoc J; 1984 Oct 01; 131(7):744-8. PubMed ID: 6383591
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).
    Czarnetzki BM, Macher E, Suciu S, Thomas D, Steerenberg PA, Rümke P.
    Eur J Cancer; 1993 Oct 01; 29A(9):1237-42. PubMed ID: 8343260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.